03.10 23:22 | dpa-AFX: AbbVie Cuts Q3, FY Adj. EPS Outlook |
03.10 22:46 | dpa-AFX: *ABBVIE EXPECTS Q3 ADJ. EPS TO BE $2.88 - $2.92 |
03.10 22:45 | dpa-AFX: *ABBVIE CUTS FY ADJ. EPS OUTLOOK TO $10.67 - $10.87 FROM PRIOR ESTIMATIONS OF $10.71 - $10.91 |
28.09 08:43 | dpa-AFX: AbbVie Submits BLA To FDA For Telisotuzumab Vedotin In Previously Treated Non-Small Cell Lung Cancer |
26.09 14:40 | dpa-AFX: AbbVie: Tavapadon Meets Primary, Secondary Endpoints In Phase 3 Trial In Early Parkinson's Disease |
26.09 14:04 | dpa-AFX: *ABBVIE ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF TAVAPADON IN PARKINSON'S DISEASE |
25.09 14:47 | dpa-AFX: AbbVie: Upadacitinib Phase 3 Trials' Post-hoc Analysis Show Positive Results In Atopic Dermatitis |
25.09 13:05 | dpa-AFX: *ABBVIE ANNOUNCES POSITIVE RESULTS FROM NEW POST-HOC ANALYSIS FROM MEASURE UP 1 AND MEASURE UP 2 PHASE 3 STUDIES |
20.09 13:55 | dpa-AFX: AbbVie: CHMP Adopts Positive Opinion For Mirvetuximab Soravtansine |
20.09 13:34 | dpa-AFX: *ABBVIE GETS POSITIVE CHMP OPINION FOR MIRVETUXIMAB SORAVTANSINE FOR THE TREATMENT OF ADULT OVARIAN CANCER |
10.09 13:08 | dpa-AFX: AbbVie Says Health Canada Approves CONSTELLA To Treat Functional Constipation In Pediatric Patients |
10.09 13:02 | dpa-AFX: *HEALTH CANADA APPROVES ABBVIE'S CONSTELLA FOR THE TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS |
06.09 16:54 | dpa-AFX: *ABBVIE (ABBV) DECLARES QUARTERLY DIVIDEND OF $ 1.55, RECORD DATE 10/15/2024 |
06.09 16:18 | dpa-AFX: *ABBVIE DECLARES QUARTERLY CASH DIVIDEND OF $1.55/SHR, PAYABLE NOV. 15, RECORD OCT. 15 |
04.09 14:19 | dpa-AFX: AbbVie: CDA Issues Positive Reimbursement Recommendation For VRAYLAR In Treatment Of Schizophrenia |
04.09 14:03 | dpa-AFX: *ABBVIE'S VRAYLAR GETS POSITIVE REIMBURSEMENT RECOMMENDATION IN CANADA FOR SCHIZOPHRENIA TREATMENT |
20.08 02:59 | dpa-AFX: AbbVie's Tepkinly Gets Conditional EU Approval For Relapsed Or Refractory Follicular Lymphoma |
16.08 10:31 | US-Regierung/Pharmakonzerne einigen sich auf niedrigere Medikamentenpreise |
15.08 16:15 | dpa-AFX: AbbVie Says Ontario, Quebec To Reimburse Epkinly Treatment Cost For Diffuse Large B Cell Lymphoma |
15.08 15:16 | dpa-AFX: *ABBVIE REPORTS ONTARIO&QUEBEC TO REIMBURSE EPCORITAMAB FOR DIFFUSE LARGE B-CELL LYMPHOMA UNDER NEW EARLY ACCESS PROCESS |
|